131 related articles for article (PubMed ID: 24050818)
1. Pathological features of FTLD-FUS in a Japanese population: analyses of nine cases.
Kobayashi Z; Kawakami I; Arai T; Yokota O; Tsuchiya K; Kondo H; Shimomura Y; Haga C; Aoki N; Hasegawa M; Hosokawa M; Oshima K; Niizato K; Ishizu H; Terada S; Onaya M; Ikeda M; Oyanagi K; Nakano I; Murayama S; Akiyama H; Mizusawa H
J Neurol Sci; 2013 Dec; 335(1-2):89-95. PubMed ID: 24050818
[TBL] [Abstract][Full Text] [Related]
2. FUS pathology in basophilic inclusion body disease.
Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
[TBL] [Abstract][Full Text] [Related]
3. Distinct pathological subtypes of FTLD-FUS.
Mackenzie IR; Munoz DG; Kusaka H; Yokota O; Ishihara K; Roeber S; Kretzschmar HA; Cairns NJ; Neumann M
Acta Neuropathol; 2011 Feb; 121(2):207-18. PubMed ID: 21052700
[TBL] [Abstract][Full Text] [Related]
4. Transportin1: a marker of FTLD-FUS.
Brelstaff J; Lashley T; Holton JL; Lees AJ; Rossor MN; Bandopadhyay R; Revesz T
Acta Neuropathol; 2011 Nov; 122(5):591-600. PubMed ID: 21847626
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic variability within the inclusion body spectrum of basophilic inclusion body disease and neuronal intermediate filament inclusion disease in frontotemporal lobar degenerations with FUS-positive inclusions.
Gelpi E; Lladó A; Clarimón J; Rey MJ; Rivera RM; Ezquerra M; Antonell A; Navarro-Otano J; Ribalta T; Piñol-Ripoll G; Pérez A; Valldeoriola F; Ferrer I
J Neuropathol Exp Neurol; 2012 Sep; 71(9):795-805. PubMed ID: 22892522
[TBL] [Abstract][Full Text] [Related]
6. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
[TBL] [Abstract][Full Text] [Related]
7. Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration.
Kawakami I; Kobayashi Z; Arai T; Yokota O; Nonaka T; Aoki N; Niizato K; Oshima K; Higashi S; Katsuse O; Hosokawa M; Hasegawa M; Akiyama H
Acta Neuropathol Commun; 2016 Apr; 4():36. PubMed ID: 27044537
[TBL] [Abstract][Full Text] [Related]
8. Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain.
Aoki N; Higashi S; Kawakami I; Kobayashi Z; Hosokawa M; Katsuse O; Togo T; Hirayasu Y; Akiyama H
Acta Neuropathol; 2012 Sep; 124(3):383-94. PubMed ID: 22526020
[TBL] [Abstract][Full Text] [Related]
9. An autopsy case of frontotemporal lobar degeneration with the appearance of fused in sarcoma inclusions (basophilic inclusion body disease) clinically presenting corticobasal syndrome.
Matsumoto A; Suzuki H; Fukatsu R; Shimizu H; Suzuki Y; Hisanaga K
Neuropathology; 2016 Feb; 36(1):77-87. PubMed ID: 26227957
[TBL] [Abstract][Full Text] [Related]
10. Neuronal intermediate filament inclusion disease may be incorrectly classified as a subtype of FTLD-FUS.
Bieniek KF; Josephs KA; Lin WL; Dickson DW
Free Neuropathol; 2020; 1():. PubMed ID: 34386806
[TBL] [Abstract][Full Text] [Related]
11. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
12. The spectrum and severity of FUS-immunoreactive inclusions in the frontal and temporal lobes of ten cases of neuronal intermediate filament inclusion disease.
Armstrong RA; Gearing M; Bigio EH; Cruz-Sanchez FF; Duyckaerts C; Mackenzie IR; Perry RH; Skullerud K; Yokoo H; Cairns NJ
Acta Neuropathol; 2011 Feb; 121(2):219-28. PubMed ID: 20886222
[TBL] [Abstract][Full Text] [Related]
13. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
Seelaar H; Klijnsma KY; de Koning I; van der Lugt A; Chiu WZ; Azmani A; Rozemuller AJ; van Swieten JC
J Neurol; 2010 May; 257(5):747-53. PubMed ID: 19946779
[TBL] [Abstract][Full Text] [Related]
14. Unusual clinical presentation and neuropathology in two subjects with fused-in sarcoma (FUS) positive inclusions.
Hartikainen PH; Pikkarainen M; Hänninen T; Soininen H; Alafuzoff I
Neuropathology; 2012 Feb; 32(1):60-8. PubMed ID: 21518013
[TBL] [Abstract][Full Text] [Related]
15. Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.
Davidson YS; Robinson AC; Hu Q; Mishra M; Baborie A; Jaros E; Perry RH; Cairns NJ; Richardson A; Gerhard A; Neary D; Snowden JS; Bigio EH; Mann DM
Neuropathol Appl Neurobiol; 2013 Feb; 39(2):157-65. PubMed ID: 22497712
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS.
Gittings LM; Foti SC; Benson BC; Gami-Patel P; Isaacs AM; Lashley T
Acta Neuropathol Commun; 2019 Feb; 7(1):18. PubMed ID: 30755280
[TBL] [Abstract][Full Text] [Related]
17. The presence of heterogeneous nuclear ribonucleoproteins in frontotemporal lobar degeneration with FUS-positive inclusions.
Gami-Patel P; Bandopadhyay R; Brelstaff J; Revesz T; Lashley T
Neurobiol Aging; 2016 Oct; 46():192-203. PubMed ID: 27500866
[TBL] [Abstract][Full Text] [Related]
18. Expanding the Phenotype of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FUS).
Chornenka K; Hirsch-Reinshagen V; Perez-Rosendahl M; Feldman H; Segal-Gidan F; Vinters HV; Mackenzie IR
J Neuropathol Exp Neurol; 2020 Jul; 79(7):809-812. PubMed ID: 32483606
[TBL] [Abstract][Full Text] [Related]
19. FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.
Page T; Gitcho MA; Mosaheb S; Carter D; Chakraverty S; Perry RH; Bigio EH; Gearing M; Ferrer I; Goate AM; Cairns NJ; Thorpe JR
J Mol Neurosci; 2011 Nov; 45(3):409-21. PubMed ID: 21603978
[TBL] [Abstract][Full Text] [Related]
20. Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.
Troakes C; Hortobágyi T; Vance C; Al-Sarraj S; Rogelj B; Shaw CE
Neuropathol Appl Neurobiol; 2013 Aug; 39(5):553-61. PubMed ID: 22934812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
